Stock Mover of the Day: Delcath Systems Inc (NASDAQ:DCTH) Q2 2016 Sentiment Report

November 16, 2016 - By Adrian Mccoy   ·   0 Comments

Stock Mover of the Day: Delcath Systems Inc (NASDAQ:DCTH)  Q2 2016 Sentiment Report

Sentiment for Delcath Systems Inc (NASDAQ:DCTH)

Delcath Systems Inc (NASDAQ:DCTH) institutional sentiment decreased to 1.13 in 2016 Q2. Its down -0.30, from 1.43 in 2016Q1. The ratio fall, as 9 hedge funds opened new and increased holdings, while 8 cut down and sold their holdings in Delcath Systems Inc. The hedge funds in our partner’s database reported: 1.85 million shares, down from 2.26 million shares in 2016Q1. Also, the number of hedge funds holding Delcath Systems Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 7 Reduced: 1 Increased: 7 New Position: 2.

Delcath Systems, Inc. is a late-stage clinical development firm with early commercial activity in Europe focused on cancers of the liver. The company has a market cap of $5.13 million. The Firm is a specialty pharmaceutical and medical device firm developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System . It currently has negative earnings. The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT).

About 75,595 shares traded hands. Delcath Systems, Inc. (NASDAQ:DCTH) has declined 58.01% since April 14, 2016 and is downtrending. It has underperformed by 62.69% the S&P500.

According to Zacks Investment Research, “Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.”

Bank Of America Corp De holds 0% of its portfolio in Delcath Systems, Inc. for 4,604 shares. Barclays Plc owns 15 shares or 0% of their US portfolio. Moreover, Blackrock Fund Advisors has 0% invested in the company for 4,024 shares. The California-based Blackrock Institutional Trust Company N.A. has invested 0% in the stock. Citadel Advisors Llc, a Illinois-based fund reported 157,333 shares.#img1#

DCTH Company Profile

Delcath Systems, Inc., incorporated on August 5, 1988, is a late-stage clinical development firm with early commercial activity in Europe focused on cancers of the liver. The Firm is a specialty pharmaceutical and medical device firm developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

More recent Delcath Systems, Inc. (NASDAQ:DCTH) news were published by: Prnewswire.com which released: “Delcath Announces Third Quarter Financial Results” on November 11, 2016. Also Marketwatch.com published the news titled: “Delcath Systems Inc.” on December 22, 2009. Prnewswire.com‘s news article titled: “Delcath Issues Letter to Stockholders” with publication date: October 18, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Adrian Mccoy


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>